VTNE Study Guide 2026

A lipopolysaccharide called endotoxin is a part of the gram-negative bacteria's outer cell wall. It is expelled from the bacteria during cell lysis and death as well as bacterial development. Endotoxin produces and releases biochemical mediators when it binds receptors on host endothelium cells, macrophages, monocytes, or polymorphonuclear leukocytes. These mediators include proteases, toxic oxygen radicals, platelet activation factor, nitric oxide, cytokines, eicosanoids, and vasoactive amines. Initiating physiologic processes that lead to endotoxic shock with cardiopulmonary dysfunction, loss of microvascular integrity, and multiple organ failure, these mediators' release. Because they are known to decrease cytokine production, stop the inflammatory cascade, and inhibit nitrous oxide, glucocorticoids are used to treat endotoxic shock. Endotoxic shock is treated with lazaroids, nonsteroidal anti-inflammatories, pentoxifylline, and nitrous oxide inhibitors but not with antibiotics.

Normal canine rectal temperature is 100.5–102.5°F; 104.5°F falls in the mild to moderate hyperthermia range, with severe hyperthermia typically above 106°F.

A periodontal probe, marked in millimeter increments, is inserted into the gingival sulcus to measure pocket depth and attachment loss.

The Baermann technique is specifically designed to recover live nematode larvae from a fresh fecal sample. It relies on the active migration of larvae out of the feces and into surrounding water. It is the preferred method for detecting lungworm larvae (e.g., Aelurostrongylus abstrusus) and other parasites that pass larvae instead of eggs in the stool.

The generally accepted standard for steam sterilization in a gravity-displacement autoclave is exposure to 121°C (250°F) at a pressure of 15 psi for a minimum of 13-15 minutes. The 5-minute cycle is typically reserved for "flash" sterilization of unwrapped instruments in a pre-vacuum sterilizer.

rh-EPO is a treatment for anemia in both humans and animals with chronic renal failure. It is prescribed at doses of 50-100 U/kg 3 times per week subcutaneously until the goal PCV is reached and is appropriate when the PCV declines to 25% or below. To track progress, patient PCV should be measured twice a week. Rh-EPO may be administered twice weekly once the target PCV is attained. A larger dose of rh-EPO may be administered to non-responsive patients. The dose can be raised in increments of 25–50 U/kg. Although there is no known maximum dose, weekly doses of up to 1050 U/kg have been documented. Reticulocytosis and a daily PCV rise of 0.5%–1.0% are present in responsive patients. In both dogs and cats, the occurrence of antibody production is very common.